 Antony Waste Handling Cell Ltd Q2 FY2026 consolidated net profit down QoQ to Rs. 13.65 crores
Antony Waste Handling Cell Ltd Q2 FY2026 consolidated net profit down QoQ to Rs. 13.65 crores Eiko Lifesciences Ltd Q2FY26 consolidated PAT increases to Rs. 1.07 crore
Eiko Lifesciences Ltd Q2FY26 consolidated PAT increases to Rs. 1.07 crore LG Balakrishnan and Bros Ltd Q2 FY2026 consolidated net profit soars to Rs. 93.62 crores
LG Balakrishnan and Bros Ltd Q2 FY2026 consolidated net profit soars to Rs. 93.62 crores Mahindra Holidays and Resorts India Ltd posts higher consolidated PAT of Rs. 17.85 crores in Q2FY26
Mahindra Holidays and Resorts India Ltd posts higher consolidated PAT of Rs. 17.85 crores in Q2FY26 Balkrishna Industries Ltd consolidated Q2FY26 PAT falls to Rs. 273.19 crores
Balkrishna Industries Ltd consolidated Q2FY26 PAT falls to Rs. 273.19 crores 
              Improved growth visibility and timely capacity expansions to remain key re-rating triggers, reiterate BUY
Our view
CCL's earnings narrowly missed our estimates despite strong topline and volume growth given higher green coffee and logistics inflation. Utilization rates in both India and Vietnam are optimum with the expanded Vietnam capacity coming onstream in 3Q and the next phase of expansion to be commissioned by Q3FY23. The India branded business also remains on track with a solid 40% growth in 9MFY22. Given a strong order book and no signs of order deferments, the management has maintained 15% plus volume growth guidance for FY22 while revenue growth can be north of 25%. While optically margins can come off marginally in percentage terms, they should continue moving up on per kg basis with an improving product mix in favor of value-added coffee variants and enhanced small pack capacity coming onstream. We continue to like the company given its cost and market leadership in instant coffee processing, successful product and market development initiatives in developed markets like US/Europe, strong traction in the India branded business, strong balance sheet and well planned timely capacity expansions. With a 25% plus earnings trajectory over next two years with stable 22-23% ROCE, we see a re-rating towards our target multiple of 20x.
Result Highlights